EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> The FDA cleared Transgene to start a phase 1 trial of its personalized immunotherapy TG4050 in ovarian cancer patients. NEC is co-financing the cancer vaccine trial. Release

> UniQure posted updated data on its hemophilia B gene therapy. The data show the high Factor IX activity seen early in the study has been sustained up to six months. Statement

> A phase 2 trial of Modus Therapeutics’ sickle cell disease drug failed to show a meaningful benefit. The setback led Modus to weigh its options for further development of the asset. Release  

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> TreeFrog Therapeutics raised €7 million ($7.8 million). The French startup aims to move one of its cell therapy research programs into humans in 2024. Statement 

> Pfizer nominated a preclinical development candidate under its collaboration with Sosei Heptares, triggering a $3 million milestone payment. The partners are yet to disclose the target of the small molecule. Release  

> Ixaltis completed phase 2 development of its urinary incontinence drug, litoxetine, setting the French biotech up to move into phase 3. Statement  

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.